BSX director reports 10b5-1 sales; holdings now 24,134 shares

Rhea-AI Filing Summary

Boston Scientific (BSX): Director stock sale reported on Form 4. A company director sold 9,990 shares of common stock on 10/27/2025 at a weighted average price of $101.1312 and 2,901 shares on 10/28/2025 at a weighted average price of $102.2402. The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025.

Following these sales, the reporting person directly beneficially owns 24,134 shares. Weighted average prices reflect multiple trades within the disclosed ranges, and full trade breakdowns are available upon request.

Insider Trade Summary

Net Seller: 12,891 shares ($1,306,900)

Net Sell 2 txns

Insider Zane Ellen M

Role Director

Sold 12,891 shs ($1.31M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,901	$102.2402	$297K
Sale	Common Stock	9,990	$101.1312	$1.01M

Holdings After Transaction: Common Stock — 24,134 shares (Direct)

Footnotes (1)

1. The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.57 to $101.405, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.165 to $102.31, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zane Ellen M

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2025		S(1)		9,990	D	$101.1312(2)	27,035	D
Common Stock	10/28/2025		S(1)		2,901	D	$102.2402(3)	24,134	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025.

2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $100.57 to $101.405, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.165 to $102.31, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Susan Thompson, Attorney-in-Fact	10/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Boston Scientific (BSX) disclose in this Form 4?

A director sold 9,990 shares on 10/27/2025 at $101.1312 (weighted average) and 2,901 shares on 10/28/2025 at $102.2402 (weighted average).

How many BSX shares does the reporting person hold after the transactions?

The reporting person directly beneficially owns 24,134 shares after the reported sales.

Were the BSX stock sales under a Rule 10b5-1 plan?

Yes. The sales were effected under a pre-established Rule 10b5-1 trading plan adopted on July 25, 2025.

What were the price ranges for the weighted average sale prices?

On 10/27/2025: $100.57–$101.405. On 10/28/2025: $102.165–$102.31.

What is the insider’s relationship to Boston Scientific (BSX)?

The reporting person is a Director of Boston Scientific.